Hetlioz tasimelteon regulatory update

The European Commission approved an MAA from Vanda for Hetlioz tasimelteon to treat non-24-hour sleep-wake disorder in blind adults. FDA approved the melatonin MT1 and MT2 receptor agonist in January....